泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Oncogene：过表达miR-200a能够促进膀胱癌浸润

2019-12-12 AlexYang MedSci原创

膀胱癌小RNA治疗靶标
关注

浸润性膀胱癌（BC）是最为致死性恶性泌尿肿瘤转移。尽管已经有研究报道miR-200a是一个致瘤性miRNA，并在子宫内膜癌中靶向PTEN基因，但是其在BC浸润过程中的生物学意义仍旧未知。最近，有研究人员发现miR-200a在人类BC组织和BBN诱导的肌肉浸润性BC组织中明显过表达。miR-200a的过表达能够特异性的通过转录上调基质金属蛋白酶（MMP）-2来促进人类BC细胞的浸润，而非迁移。机制研

浸润性膀胱癌（BC）是最为致死性恶性泌尿肿瘤转移。尽管已经有研究报道miR-200a是一个致瘤性miRNA，并在子宫内膜癌中靶向PTEN基因，但是其在BC浸润过程中的生物学意义仍旧未知。

最近，有研究人员发现miR-200a在人类BC组织和BBN诱导的肌肉浸润性BC组织中明显过表达。miR-200a的过表达能够特异性的通过转录上调基质金属蛋白酶（MMP）-2来促进人类BC细胞的浸润，而非迁移。机制研究表明了c-Jun的磷酸化能够介导MMP-2 mRNA转录水平的增加。进一步的调查阐释了Dicer在miR-200a过表达的BC细胞中减少；从而抑制miR-16成熟，并随后导致JNK2蛋白翻译和c-Jun激活的增加。总结来讲，他们的研究表明了miR-200a的过表达能够抑制Dicer的表达，反过来可以抑制miR-16的成熟和上调JNK2表达、c-Jun磷酸化、MMP-2转录和BC浸润。

最后，研究人员指出，他们的结果表明了miR-200a是一个致瘤性miRNA，是BC浸润的一个正调控因子。他们的发现在治疗浸润性BC患者新策略开发中是非常有用的。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958201, encodeId=4d971958201ae, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat Aug 29 15:14:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049260, encodeId=08a0204926015, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Jan 30 13:14:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930748, encodeId=b1bb1930e48ab, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 23 14:14:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558176, encodeId=4fd715581e69a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Dec 14 04:14:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039958, encodeId=86851039958f5, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 12 16:14:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2020-08-29 lq1767

    #过表达#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1958201, encodeId=4d971958201ae, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat Aug 29 15:14:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049260, encodeId=08a0204926015, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Jan 30 13:14:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930748, encodeId=b1bb1930e48ab, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 23 14:14:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558176, encodeId=4fd715581e69a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Dec 14 04:14:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039958, encodeId=86851039958f5, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 12 16:14:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2020-01-30 cy0324

    #Gene#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1958201, encodeId=4d971958201ae, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat Aug 29 15:14:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049260, encodeId=08a0204926015, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Jan 30 13:14:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930748, encodeId=b1bb1930e48ab, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 23 14:14:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558176, encodeId=4fd715581e69a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Dec 14 04:14:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039958, encodeId=86851039958f5, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 12 16:14:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2020-06-23 smallant2002

    #miR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1958201, encodeId=4d971958201ae, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat Aug 29 15:14:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049260, encodeId=08a0204926015, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Jan 30 13:14:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930748, encodeId=b1bb1930e48ab, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 23 14:14:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558176, encodeId=4fd715581e69a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Dec 14 04:14:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039958, encodeId=86851039958f5, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 12 16:14:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2019-12-14 zsyan

    #Oncogene#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1958201, encodeId=4d971958201ae, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat Aug 29 15:14:00 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049260, encodeId=08a0204926015, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Jan 30 13:14:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930748, encodeId=b1bb1930e48ab, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jun 23 14:14:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558176, encodeId=4fd715581e69a, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Dec 14 04:14:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039958, encodeId=86851039958f5, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 12 16:14:00 CST 2019, time=2019-12-12, status=1, ipAttribution=)]
    2019-12-12 留走人康

    膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效

    0

相关资讯

Cancer：保险额不足对小于65岁个体膀胱癌诊断、生存和医疗服务的影响

健康保险是医疗保险差异的关键调控因素。其中一种花费最高的疾病-膀胱癌，对患者的保险状态非常敏感。研究人员利用监测、流行病学、最终结果登记和国家癌症数据库来确定从2007年到2014年被诊断为膀胱癌的且65岁以下的个体，并评估了保险状态与随后结果的关系。研究发现，与那些具有私人保险的相比，没有保险或者只有医疗保险的个体诊断为肌肉浸润性膀胱癌的比例高出1倍（没有保险个体OR， 1.90； 95%CI，

Oncogene：Hsa_circ_0001361可通过miR-491-5p/MMP9途径促进膀胱癌的浸润和转移

环状RNAs（circRNAs）在各种恶性肿瘤的发展和恶化过程中起着重要的作用。之前的高通量测序研究表明了在膀胱癌中有几百个circRNAs表达异常，并且有研究人员确定了下调的circRNAs circHIPK3、circRNA BCRC-3和circNR3C1在BC的恶化过程中具有抑制作用。最近，有研究人员聚焦于表达上调的circRNAs，并利用RNA-Seq和qRT-PCR鉴定了一个新的环状R

Sci Rep：鳞状/腺体组织学变异高风险NMIBC的BCG滴注与根治性膀胱切除术比较

最近，有研究人员评估了卡介苗（BCG）滴注与根治性膀胱切除术对鳞状/腺体组织学变异高风险NMIBC的治疗效果情况。研究人员回顾了高风险NMIBC患者的数据，数据的时间为2000年1月到2017年12月。他们对鳞状/腺体组织学变异高风险NMIBC患者的根治性膀胱切除术治疗、膀胱内卡介苗治疗和观察组进行了比较分析。研究共包括了1263名高风险NMIBC患者，其中62名（4.9%）报道具有鳞状/腺体组织

Brit J Cancer：系统的化学筛选鉴定的disulfiram能够增强膀胱癌对顺铂的敏感性

由于化疗抗性的产生，标准的吉西他滨与顺铂(GC)化疗对晚期膀胱癌的治疗效果有限，增强对GC的敏感性也是一个临床挑战。最近，有研究人员对已知的化学药物和可替代药物进行了高通量筛选，共包括了2098种化合物。研究人员对那些能够增强GC效果的化学药物进行了筛选。研究发现，在多个细胞系中，一种抗酒精药物disulfiram（DSF）能够与顺铂表现出协同效应，而与吉西他滨并没有上述效应。共同施加DSF与GC

Oncogene：FOXA1的高甲基化和 PTEN等位基因的缺失能够促进鳞状分化和膀胱癌异质性

膀胱癌中的瘤内异质性是进行准确分子分型和良好治疗效果的障碍。然而，肿瘤异质性的个体细胞和机制贡献是有争议的。最近，有研究人员调查了FOXA1和PTEN去激活在膀胱癌中的潜在机制，并探究了对肿瘤异质性的贡献情况。这些分析在去激活的FOXA1和PTEN中间型和腔型小鼠尿路上皮细胞中进行。研究发现，FOXA1和PTEN的去激活和表达减弱在人类疾病中广泛存在，且FOXA1和PTEN在等位基因缺失和位点特异

Nat Commun：在膀胱癌进展中c-Met激活能够引起TGFβ受体调控网络的建立

肌肉浸润性膀胱癌的治疗仍旧是一个很大的临床挑战。异常的HGF/c-MET上调和激活在膀胱癌中总是出现并且与癌症恶化和浸润相关。然而，HGF/c-MET调节的浸润的潜在机制在膀胱癌中仍旧未知。作为负调控回路的一部分，SMAD7能够与SMURF2结合靶向TGFβ受体使其降解。在这些条件下，SMAD7可以通过干扰SMURF2分子内的相互作用起到SMURF2拮抗剂的作用。在他们的研究中，研究人员阐释了HG